Drug Shortage Report for LUTATHERA
Report ID | 160113 |
Drug Identification Number | 02484552 |
Brand name | LUTATHERA |
Common or Proper name | Lutetium (177Lu) oxodotreotide |
Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | LUTETIUM |
Strength(s) | 370MBq |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 370 MBq in 1 single dose vial |
ATC code | V10XX |
ATC description | |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-05-02 |
Actual start date | 2022-05-02 |
Estimated end date | 2022-06-13 |
Actual end date | 2022-06-13 |
Shortage status | Resolved |
Updated date | 2022-06-14 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2022-06-14 | English | Compare |
v3 | 2022-06-07 | English | Compare |
v2 | 2022-05-06 | French | Compare |
v1 | 2022-05-06 | English | Compare |
Showing 1 to 4 of 4